Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 10, 1999, Pages 1323-1328

  Torkvist L ^a,b   Thorlacius, H ^a   Sjoqvist U ^c   Bohman, L ^c   Lapidus, A ^c   Flood, L ^c   Agren B ^c   Raud, J ^a   Lofberg R ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; GLUCOCORTICOID; LOW MOLECULAR WEIGHT HEPARIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; FEMALE; HEMATOMA; HISTOPATHOLOGY; HUMAN; INTESTINE ENDOSCOPY; LEUKOCYTE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCINTIGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; ULCERATIVE COLITIS;

ADULT; AGED; ANTICOAGULANTS; CHEMOTHERAPY, ADJUVANT; COLITIS, ULCERATIVE; FEMALE; GLUCOCORTICOIDS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M EXAMETAZIME;

EID: 0032847644     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00599.x     Document Type: Article

References (18)

1. 1 Fazio V. Current status of surgery for inflammatory bowel disease. Digestion 1998; 59: 470-80.
2. 2 Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
3. 3 Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998; 59: 453-69.
4. 4 Gaffney PR, Doyle CT, Gaffeny A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-3.
5. 5 Evans RC, Wong Shim V, Morris AI, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 1997; 11: 1037-40.
6. 6 Brazier F, Yzet T, Borochwicz A, Colomber J, Duchman J, Dupas J. Treatment of ulcerative colitis with heparin. Gastroenterology 1996; 110: A872(Abstract).
7. 7 Folwaczny C, Spannagl M, Wibecke W, Jochum M, Heldwein W, Loeschke K. Heparin in the treatment of highly active inflammatory bowel disease. Gastroenterology 1996; 110: A908(Abstract).
8. 8 Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995; 37: 585-8.
9. 9 Brazier F, Yzet T, Duchman J, Iglicki F, Dupas J. Effect of heparin treatment on extraintestinal manifestations associated with inflammatory bowel disease. Gastroenterology 1996; 110: A872(Abstract).
10. 10 Talbot R, Heppell J, Doziois R, Beart R. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61: 140-5.
11. 11 Dhillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992; 21: 127-33.
12. 12 Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel diseases. Gut 1995; 36: 724-30.
13. 13 Patel RT, Pall AA, Keigheley MR. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 1037-41.
14. 14 Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Stand J Gastroenterol 1997; 32: 401-10.
15. 15 Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L-and P-selectins and inhibit acute inflammation. Blood 1993; 82: 3253-8.
16. 16 Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
17. 17 Xie X, Thorlacius H, Raud J, Hedqvist P, Lindbom L. Inhibitory effect of locally administered heparin on leucocyte rolling and chemoattractant-induced firm adhesion in the rat mesenteric venules in vivo. Br J Pharmacol 1997; 122: 906-10.
18. 18 Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355-64.